Streetbeat News

Analyst Ratings

PGNY

Leerink Partners has maintained a Market Perform rating on Progyny (NASDAQ:PGNY) but lowered its price target from $25 to $21, indicating a more cautious outlook.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 1:09 pm

HALO

JP Morgan analyst Jessica Fye has downgraded Halozyme Therapeutics from Overweight to Neutral, while raising the price target from $52 to $57.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 1:08 pm

AGIO

RBC Capital analyst Gregory Renza has reiterated an Outperform rating for Agios Pharmaceuticals, maintaining a price target of $55.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 1:08 pm

FIVE

JP Morgan analyst Matthew Boss has downgraded Five Below (NASDAQ:FIVE) from Neutral to Underweight, while raising the price target from $89 to $95.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 1:05 pm

FDMT

Leerink Partners has reiterated its Outperform rating for 4D Molecular Therapeutics (NASDAQ:FDMT) but lowered the price target from $40 to $36.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 1:05 pm

ALNY

RBC Capital analyst Luca Issi has reiterated an Outperform rating for Alnylam Pharmaceuticals, maintaining a price target of $300.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 1:04 pm

APLT

Leerink Partners has maintained an 'Outperform' rating on Applied Therapeutics (NASDAQ:APLT) and raised the price target from $11 to $14, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 1:01 pm

NEP

Jefferies has initiated coverage on NextEra Energy Partners with a Buy rating and set a price target of $28.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 1:01 pm

RRX

Regal Rexnord (NYSE:RRX) has received mixed analyst ratings over the past three months, with a majority being bullish. Analysts have set a 12-month average price target of $195.6, slightly up from the previous $195.00. The company's financials show a decline in revenue growth but strong net margin, ROE, and ROA, despite a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 19, 2024 | 1:01 pm

VSTO

Vista Outdoor (NYSE:VSTO) has received mixed analyst ratings, with a recent average price target of $41.17, reflecting a slight increase. The company's financials show a decline in revenue but strong profitability and effective debt management.

Portfolio Pulse from Benzinga Insights

September 19, 2024 | 1:01 pm